Skip to main content

Advertisement

SpringerLink
Log in

Disease management strategies to optimize cardiovascular risk in type 2 diabetes mellitus

  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

A number of disease management strategies have been developed in the past decade to reduce cardiovascular (CV) risk in adults with type 2 diabetes. On average, such programs improve glycated hemoglobin (A1c) only 0.5% and often have little or no effect on blood pressure control or low-density lipoprotein (LDL) control, which are critically important CV risk factors. In a large randomized Medicare demonstration program, diabetes disease management programs were unable to recover fees through cost savings to the Centers for Medicare and Medicaid Services. Available data suggest several strategies to improve the effectiveness and reduce the cost of diabetes disease management: 1) integrate disease management operationally and fiscally with primary care; 2) focus on treatment intensification; 3) focus on blood pressure, LDL, aspirin use, and smoking cessation as well as glucose control; and 4) individualize patient goals based on potential CV risk reduction potential and patient preference to maximize clinical benefit and return on investment for each patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Gilmer TP, O’Connor PJ, Rush WA, et al.: Predictors of health care costs in adults with diabetes. Diabetes Care 2005, 28:59–64.

    Article  PubMed  Google Scholar 

  2. Haffner SM, Lehto S, Rönnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234.

    Article  PubMed  CAS  Google Scholar 

  3. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393.

    Article  PubMed  Google Scholar 

  4. Gaede P, Valentine WJ, Palmer AJ, et al.: Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008, 31:1510–1515.

    Article  PubMed  Google Scholar 

  5. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580–591.

    Article  PubMed  CAS  Google Scholar 

  6. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755–1762.

    Article  PubMed  CAS  Google Scholar 

  7. Pyŏrälä K, Pedersen TR, Kjekshus J, et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20:614–620.

    Article  PubMed  Google Scholar 

  8. Holman RR, Paul SK, Bethel MA, et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577–1589.

    Article  PubMed  CAS  Google Scholar 

  9. Patel A, ADVANCE Collaborative Group, MacMahon S, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829–840.

    Article  PubMed  CAS  Google Scholar 

  10. Williams TF, Martin DA, Hogan MD, et al.: The clinical picture of diabetic control, studied in four settings. Am J Public Health Nations Health 1967, 57:441–451.

    PubMed  CAS  Google Scholar 

  11. Saaddine JB, Cadwell B, Gregg EW, et al.: Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. Ann Intern Med 2006, 144:465–474.

    PubMed  Google Scholar 

  12. Hoerger TJ, Segel JE, Gregg EW, et al.: Is glycemic control improving in U.S. adults? Diabetes Care 2008, 31:81–86.

    Article  PubMed  Google Scholar 

  13. MN Community Measurement. Available at http://www.mnhealthcare.org/:_main.cfm. Accessed December 2, 2008.

  14. Sperl-Hillen JM, O’Connor PJ: Factors driving diabetes care improvement in a large medical group: ten years of progress. Am J Manag Care 2005, 11(5 Suppl):S177–S185.

    PubMed  Google Scholar 

  15. Sperl-Hillen J, O’Connor PJ, Carlson RR, et al.: Improving diabetes care in a large health care system: an enhanced primary care approach. Jt Comm J Qual Improv 2000, 26:615–622.

    PubMed  CAS  Google Scholar 

  16. Beaulieu N, Cutler DM, Ho K, et al.: The business case for diabetes disease management for managed care organizations. Forum Health Econ Policy 2006, 9(1):Article 1.

  17. Norris SL, Glasglow RE, Engelgau MM, O’Connor PJ: Chronic disease management: a definition and systematic approach to component interventions. Dis Manage Health Outcomes 2003, 11:477–488.

    Article  Google Scholar 

  18. Norris SL, Nichols PJ, Caspersen CJ, et al.: The effectiveness of disease and case management for people with diabetes. A systematic review. Am J Prev Med 2002, 22(4 Suppl):15–38.

    Article  PubMed  Google Scholar 

  19. Pope JE, Hudson LR, Orr PM: Case study of American Healthways’ diabetes disease management program. Health Care Financ Rev 2005, 27:47–58.

    PubMed  Google Scholar 

  20. Rubin RJ, Dietrich KA, Hawk AD: Clinical and economic impact of implementing a comprehensive diabetes management program in managed care. J Clin Endocrinol Metab 1998, 83:2635–2642.

    Article  PubMed  CAS  Google Scholar 

  21. Bodenheimer T: Disease management in the American market. BMJ 2000, 320:563–566.

    Article  PubMed  CAS  Google Scholar 

  22. Ferguson JA, Weinberger M: Case management programs in primary care. J Gen Intern Med 1998, 13:123–126.

    Article  PubMed  CAS  Google Scholar 

  23. Shojania KG, Ranji SR, McDonald KM, et al.: Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. JAMA 2006, 296:427–440.

    Article  PubMed  CAS  Google Scholar 

  24. Mangione CM, Gerzoff RB, Williamson DF, et al.: The association between quality of care and the intensity of diabetes disease management programs. Ann Intern Med 2006, 145:107–116.

    PubMed  Google Scholar 

  25. Karter AJ, Moffet HH, Liu J, et al.: Glycemic response to newly initiated diabetes therapies. Am J Manag Care 2007, 13:598–606.

    PubMed  Google Scholar 

  26. Schmittdiel J, Vijan S, Fireman B, et al.: Predicted quality-adjusted life years as a composite measure of the clinical value of diabetes risk factor control. Med Care 2007, 45:315–321.

    Article  PubMed  Google Scholar 

  27. McCall N, Cromwell J, Bernard S: Evaluation of Phase I of Medicare Health Support (Formerly Voluntary Chronic Care Improvement) Pilot Program Under Traditional Fee-For-Service Medicare. Available at http://www.cms.hhs.gov/reports/downloads/McCall.pdf. Accessed December 2, 2008.

  28. ADVANCE Collaborative Group, Patel A, MacMahon S, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  29. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559.

    Article  PubMed  CAS  Google Scholar 

  30. Schmittdiel JA, Uratsu CS, Karter AJ, et al.: Why don’t diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med 2008, 23:588–894.

    Article  PubMed  Google Scholar 

  31. Nyman MA, Murphy ME, Schryver PG, et al.: Improving performance in diabetes care: a multicomponent intervention. Eff Clin Pract 2000, 3:205–212.

    PubMed  CAS  Google Scholar 

  32. Sidorov J, Shull R, Tomcavage J, et al.: Does diabetes disease management save money and improve outcomes? A report of simultaneous short-term savings and quality improvement associated with a health maintenance organization-sponsored disease management program among patients fulfilling health employer data and information set criteria. Diabetes Care 2002, 25:684–689.

    Article  PubMed  Google Scholar 

  33. Phillips LS, Branch WT, Cook CB, et al.: Clinical inertia. Ann Intern Med 2001, 135:825–834.

    PubMed  CAS  Google Scholar 

  34. O’Connor PJ: Improving diabetes care by combating clinical inertia. Health Serv Res 2005, 40(6 Pt 1):1854–1861.

    Article  PubMed  Google Scholar 

  35. O’Connor PJ: Overcome clinical inertia to control systolic blood pressure. Arch Intern Med 2003, 163:2677–2678.

    Article  PubMed  Google Scholar 

  36. O’Connor PJ, Sperl-Hillen JM, Johnson PE, et al.: Clinical inertia and outpatient medical errors. In Advances in Patient Safety: From Research to Implementation. Edited by Henriksen K, Battles JB, Marks ES, Lewin DI. Rockville, MD: Agency for Healthcare Research and Quality; 2005:293–308.

    Google Scholar 

  37. Grant RW, Wald JS, Schnipper JL, et al.: Practice-linked online personal health records for type 2 diabetes mellitus: a randomized controlled trial. Arch Intern Med 2008, 168:1776–1782.

    Article  PubMed  Google Scholar 

  38. Berlowitz DR, Ash AS, Hickey EC, et al.: Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care 2003, 26:355–359.

    Article  PubMed  Google Scholar 

  39. O’Connor PJ: Improving medication adherence: challenges for physicians, payers, and policy makers. Arch Intern Med 2006, 166:1802–1804.

    Article  PubMed  Google Scholar 

  40. O’Connor PJ, Rush WA, Prochaska JO, et al.: Professional advice and readiness to change behavioral risk factors among members of a managed care organization. Am J Manag Care 2001, 7:125–130.

    PubMed  CAS  Google Scholar 

  41. Norris SL, Lau J, Smith SJ, et al.: Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care 2002, 25:1159–1171.

    Article  PubMed  Google Scholar 

  42. O’Connor PJ, Crabtree BF, Yanoshik MK: Differences between diabetic patients who do and do not respond to a diabetes care intervention: a qualitative analysis. Fam Med 1997, 29:424–428.

    PubMed  CAS  Google Scholar 

  43. Lorig KR, Ritter P, Stewart AL, et al.: Chronic disease self-management program: 2-year health status and health care utilization outcomes. Med Care 2001, 39:1217–1223.

    Article  PubMed  CAS  Google Scholar 

  44. Funnell MM, Anderson RM: Working toward the next generation of diabetes self-management education. Am J Prev Med 2002, 22(4 Suppl):3–5.

    Article  PubMed  Google Scholar 

  45. Dunn SM: Rethinking the models and modes of diabetes education. Patient Educ Couns 1990, 16:281–286.

    Article  PubMed  CAS  Google Scholar 

  46. Johnson PE, Veazie PJ, Kochevar L, et al.: Understanding variation in chronic disease outcomes. Health Care Manag Sci 2002, 5:175–189.

    Article  PubMed  Google Scholar 

  47. Bolen S, Feldman L, Vassy J, et al.: Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007, 147:386–399.

    PubMed  Google Scholar 

  48. Kahn R, Robertson RM, Smith R, Eddy D: The impact of prevention on reducing the burden of cardiovascular disease. Diabetes Care 2008, 31:1686–1696.

    Article  PubMed  Google Scholar 

  49. CDC Diabetes Cost-Effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002, 287:2542–2551.

    Article  Google Scholar 

  50. Institute for Clinical Systems Improvement: Primary Prevention of Chronic Disease Risk Factors (Guideline). Bloomington, MN: ICSI; 2008.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. HealthPartners Research Foundation, PO Box 1524, MS #21111R, Minneapolis, MN, 55440, USA

    Patrick J. O’Connor

Authors
  1. Patrick J. O’Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. JoAnn M. Sperl-Hillen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas E. Kottke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick J. O’Connor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O’Connor, P.J., Sperl-Hillen, J.M. & Kottke, T.E. Disease management strategies to optimize cardiovascular risk in type 2 diabetes mellitus. Curr Cardio Risk Rep 3, 71–77 (2009). https://doi.org/10.1007/s12170-009-0012-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12170-009-0012-0

Keywords

Search

Navigation